Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ceftazidime Plus Fosfomycin Versus Ceftazidime Alone for Severe Gram-negative Infections: a Triple-blind, Placebo-controlled Point-of-care Randomized Clinical Trial

NCT07063095 is registered in ClinicalTrials.gov with Angela HUTTNER as lead sponsor.

NCT NCT07063095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07063095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ceftazidime Plus Fosfomycin Versus Ceftazidime Alone for Severe Gram-negative Infections: a Triple-blind, Placebo-controlled Point-of-care Randomized Clinical Trial
Lead sponsor
Angela HUTTNER
Phase
Phase 3
Overall status
Recruiting
Start date
August 25, 2025
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gram negative infections, sepsis and septic shock